A novel neurophysiological measurement (MUNIX) in neuromuscular disorders; test-retest reliability and longitudinal follow up measurements in ALS patients
Withdrawn
- Conditions
- Lou Gehrig disease10029317
- Registration Number
- NL-OMON36377
- Lead Sponsor
- niversitair Medisch Centrum Sint Radboud
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Withdrawn
- Sex
- Not specified
- Target Recruitment
- 20
Inclusion Criteria
ALS patients must fulfill not less than the revised El Escorial category for probable, laboratory supported ALS. Symptom onset, defined as onset of weakness, must be less than 14 months ago.
Exclusion Criteria
Patients with pure upper motor neuron signs or *suspected ALS* will not be eligible for the study.
Any history of major neurological disorders that might influence MUNIX measurements (e.g. polyneuropathy, peripheral nerve damage, paresis of any cause, muscular atrophy) in ALS patients.
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>MUNIX inter-rater and intra-rater variability and reproducibility.<br /><br>Longitudinal relation of MUNIX with the revised ALS functional rating scale<br /><br>(ALSFRS-R).</p><br>
- Secondary Outcome Measures
Name Time Method <p>Correlation CMAP and MUNIX with echointensity on baseline and after 6 and 12<br /><br>months</p><br>